Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.36 |
| ▸ | NOS3 | P29474 | 3/20 | 0.36 |
| ▸ | NOS2 | P35228 | 3/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21125426 | 0.78 | GPR3 (0.42) | NOS1NOS3NOS2NSD2 | |
| SCHEMBL18659117 | 0.69 | NSD2 (0.39) | NOS1NOS3NOS2NSD2MEN1 | |
| Peganole SCHEMBL30368933 | 0.66 | KLK7 (0.50) | NOS1NOS3NOS2MEN1KMT2A | |
| Peganole SCHEMBL4111529 | 0.66 | KLK7 (0.50) | NOS1NOS3NOS2MEN1KMT2A | |
| SCHEMBL17555026 | 0.65 | MAOA (0.33) | — | |
| SCHEMBL6451245 | 0.65 | NOS1 (0.33) | NOS1NOS3NOS2 | |
| SCHEMBL21086644 | 0.64 | LMNA (0.40) | MEN1KMT2AATM | |
| SCHEMBL21339327 | 0.64 | NOS1 (0.37) | NOS1NOS3NOS2 | |
| SCHEMBL7491186 | 0.64 | NOS3 (0.33) | NOS1NOS3NOS2 | |
| SCHEMBL9583619 | 0.64 | MAOB (0.44) | NOS3NOS2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275565-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| US-20090275565-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275565-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | NOS1 4816/4885NOS3 4528/4885NOS2 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.